Articles tagged with: Velcade
Results of a small preclinical study conducted at the Karmanos Cancer Center in Detroit indicate that the oral anesthetic dyclonine may enhance the anti-myeloma activity of Velcade.
Dyclonine is the active ingredient in the Sucrets brand of sore throat lozenges, which are sold over-the-counter in drugstores and other retailers in Canada and the United States. Sucrets lozenges are marketed by Insight Pharmaceuticals.
The Karmanos researchers conducted laboratory tests of dyclonine's activity against the so-called "RPMI8226" line of myeloma cells, which is commonly used in pre-clinical testing of potential myeloma therapies. …
French researchers earlier this week published updated results of a small Phase 2 clinical trial testing the combination of Revlimid, Velcade, and dexamethasone (RVD) in newly diagnosed multiple myeloma patients.
The researchers found that RVD, when given before and after stem cell transplantation – and when followed by maintenance therapy with Revlimid – led to very deep treatment responses and significant survival rates.
The 31 newly diagnosed patients in the French trial initially were treated with three cycles of RVD therapy. Next, the trial participants underwent autologous (own) stem cell …
This year’s American Society of Clinical Oncology (ASCO) annual meeting in Chicago ended last Tuesday.
The day before the meeting ended was the busiest day at the meeting with regard to myeloma research. It featured a session of oral presentations in the morning and a poster session in the afternoon. In addition, an education session was held in the afternoon that included one myeloma-related talk, given by Dr. Leif Bergsagel of the Mayo Clinic, about progress in the treatment of multiple myeloma (article in the ASCO 2014 Educational Book). …
Celgene Submits Revlimid For Approval As First-Line Therapy – The pharmaceutical company Celgene has announced that it has filed applications with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) seeking official approval of Revlimid (lenalidomide) as a treatment for newly diagnosed multiple myeloma. The application with the FDA was filed in April, while the EMA application was filed in February. Analysts expect the agencies to reach decisions on the applications by the middle of next year. Revlimid currently has regulatory approval in the U.S. and Europe for use in relapsed and refractory myeloma. However, Revlimid – alone or in combination with other anti-myeloma agents – is often used for the treatment of newly diagnosed patients in the United States, where such “off-label” prescribing is legally permitted. Because off-label prescribing is less common outside the U.S., a positive EMA decision in regard to the Revlimid application could significantly expand the drug's use in Europe. For more information, please see the Celgene press release regarding its 2014 first quarter earnings.
U.K. Agency Approves Velcade For Newly Diagnosed Myeloma – The National Institute for Health and Clinical Excellence (NICE), the agency that sets treatment guidelines for the U.K.'s National Health Service in England and Wales, earlier this week approved the use of Velcade (bortezomib) in newly diagnosed multiple myeloma patients eligible for stem cell transplantation. The decision specifies that Velcade is to be given in combination with dexamethasone (Decadron) or with dexamethasone and thalidomide (Thalomid). This week's NICE decision supplements a 2011 decision regarding the use of Velcade in newly diagnosed patients ineligible for transplantation. For those patients, however, NICE has approved the use of Velcade only if a patient cannot tolerate treatment with thalidomide (see related Beacon news). For more information, see the NICE press release.
New Formulation Of IV Melphalan Meets Primary Endpoint In Key Phase 2 Trial – The pharmaceutical company Spectrum Pharmaceuticals announced earlier this week that its Phase 2 pivotal trial of a new formulation of intravenous melphalan (Alkeran) met its primary endpoint. Given the results of the trial, the company is expected to file an application with the FDA during the third quarter of this year requesting permission to market the drug in the United States. The new formulation of melphalan, which Spectrum calls "Captisol-enabled melphalan", does not include propylene glycol, a chemical that has been reported to have heart- and kidney-related side effects. The Captisol technology also improves the stability of Spectrum's melphalan formulation. Together, the improved stability and lack of propylene glycol may allow Spectrum's formulation to be administered at doses higher than can be safely achieved with currently available melphalan formulations. Captisol technology also is used in the formulation of Kyprolis (carfilzomib). The primary endpoint in the pivotal Phase 2 trial of propylene gylcol-free melphalan was overall safety. The drug was tested at a dose of 200 mg/m2 in myeloma patients undergoing autologous (own) stem cell transplantation. Currently available formulations of melphalan also are typically dosed at 200 mg/m2 dose when they are used during the stem cell transplant process. For more information, please see the Spectrum Pharmaceuticals press release.
Findings from a prospective Phase 2 clinical trial indicate that the combination of Revlimid, Velcade, and dexamethasone is effective in relapsed and refractory multiple myeloma patients.
The trial enrolled 64 patients, who had been treated with a median of two prior therapies, at six different U.S. cancer centers from 2006 to 2008.
Nearly two-thirds of the patients in the trial achieved at least a partial response, despite the fact that more than half of the patients had previously been treated with Velcade (bortezomib), and nearly three quarters had …